Authors


Michaele C. Christian, MD

Latest:

Intraperitoneal Therapy for Ovarian Cancer Reconsidered

Intraperitoneal (IP) chemotherapy is a preferred treatment option that should be offered to all women for front-line treatment of stage III optimally debulked ovarian cancer. Patients should be provided with information on the survival and toxicity for both IP and intravenous (IV) therapies, as well as practical information about the administration of each regimen, so that they may play an active role in the decision-making process. When making a decision between IP and IV therapeutic options, the experience and preference of the oncologist are critical factors in determining appropriate therapy for each woman.


Michalina Janiszewska, PhD

Latest:

Tumor Heterogeneity: The Lernaean Hydra of Oncology?

Intratumor heterogeneity is one of the biggest challenges in cancer diagnosis and treatment. Despite morphologic and clinical recognition of tumor heterogeneity, an understanding of it at a molecular level has only begun to emerge in recent years.


Michel Bolla, MD

Latest:

Adjuvant Hormonal Therapy Benefits Prostate Cancer Patients Treated With Radiotherapy

To investigate the potential use of adjuvant hormonal therapy, a randomized, prospective trial was conducted among patients with locally advanced prostate cancer, comparing irradiation alone, with irradiation plus hormonal treatment with goserelin, an agonist anologue of gonadotropin-releasing hormone that reduces testosterone secretion. A total of 415 men under 80 years old with locally advanced disease and no previous treatment for prostate cancer were initially recruited, with data available for analysis on 401 of these patients. Preliminary results at 33-months’ follow-up suggested that goserelin started at the onset of external irradiation improved both local control and 5-year survival. Updated results at 45 months confirm these data. The overall 5-year survival rate for those treated with goserelin in addition to radiotherapy was 79%, compared to 62% in the radiotherapy only group. The localized control rate was 97% in the combined treatment group compared to 77% in the radiotherapy only group. [Oncol News Int 6(Suppl 3):21-22, 1997]


Michel Chazard, MD

Latest:

Impact of UFT on Tumoral TS and DPD Levels in Colorectal Cancer

This was an open lable, pilot translational clinical pharmacology study of a brief (7 day) course of UFT, 300 mg/m²/day, in combination with leucovorin, 90 mg/day, in six patients with newly diagnosed advanced colorectal cancer.


Michel Roy, MD

Latest:

Fertility-Preserving Options for Cervical Cancer

Childbearing is one of the most important life goals for many women, and fertility preservation is a very important factor in the overall quality of life of cancer survivors. Cervical cancer frequently affects young women; because some women tend to delay childbearing, fertility preservation must be considered when treatment options are discussed. Over the past decade, the radical trachelectomy procedure has become a well established fertility-preserving option for young women with early-stage cancer; this procedure is associated with low morbidity, good oncologic outcome, and a high proportion of pregnancies that reach the third trimester and babies that are delivered at term. This article will review available literature on the vaginal radical trachelectomy procedure and data from other surgical approaches, such as the abdominal radical trachelectomy. In addition, the potential future application of neoadjuvant chemotherapy followed by fertility-preserving surgery in patients with locally advanced cervical cancer will be examined. Finally, ultraconservative surgical approaches (eg, conization alone with or without laparoscopic lymphadenectomy) in very early-stage disease will be discussed.


Michel Van Gelder, MD

Latest:

Commentary (Van Gelder/Schouten)-Follicular Lymphoma: Expanding Therapeutic Options

Ganti et al present quite an extensive overview of follicular lymphoma, with most of their emphasis on clinical practice. Many of the issues they touch upon demonstrate that we cannot draw firm conclusions about the superiority of various treatments over others, due to a variety of study limitations. These challenges to interpretation include the indolent course of the disease in most patients (and thus the long follow-up needed to draw firm conclusions), the often small number of patients in this category, the retrospective nature of most studies, differences in risk factors, and the relative lack of randomized studies. As is also the case with efficacy, the most beneficial treatment strategy in follicular lymphoma remains to be established.


Michel van Kruchten, MD

Latest:

Whole-Body PET Imaging of Breast Cancer Characteristics to Improve Precision Treatment

However, it is becoming ever clearer that tumor characteristics can change during the course of disease. Given this change over time, other supporting techniques for guiding therapy would be of value. Molecular radionuclide imaging with positron emission tomography (PET) can potentially fulfill this need.


Michele Basche, MD

Latest:

Treatment of Non–Small-Cell Lung Cancer in Older Persons

The majority of individuals diagnosed with lung cancer in theUnited States are 70 years of age and older. Defining appropriatetherapy for older patients with non–small-cell lung cancer (NSCLC) isbecoming a major focus of clinical research. In this article, we reviewthe available data on clinical predictors of risk and benefit for elderlyNSCLC patients receiving treatment via a variety of modalities, includingsurgery, radiotherapy, combined radiotherapy and chemotherapy,and chemotherapy alone. The data demonstrate that subgroups ofelderly patients benefit from appropriately selected treatment. Participationof older patients in clinical trials designed to assess efficacy,toxicity, and quality-of-life outcomes for recently developed treatmentmodalities in this population is critical.


Michele Cavo, MD

Latest:

Upfront ASCT Still Best Option in Newly Diagnosed Multiple Myeloma

In this video we discuss the results of a phase III trial that studied upfront high-dose chemotherapy plus autologous stem cell transplantation (ASCT) compared to chemotherapy alone and bortezomib in newly diagnosed multiple myeloma.


Michele Y. Halyard, MD

Latest:

ACR Appropriateness Criteria® Ductal Carcinoma in Situ

Management of ductal carcinoma in situ (DCIS) commonly involves excision, radiotherapy, and hormonal therapy. Radiotherapy is employed for local control in breast conservation. Evidence is evolving for several radiotherapy techniques exist beyond standard whole-breast irradiation.


Michelle A. Springer, MS, CGC

Latest:

PALB2-Positive Breast Cancer in a 40-Year-Old Man

In July 2003, an asymptomatic 40-year-old man presented to his primary care physician for routine care and was found to have a palpable right axillary lymph node.


Michelle Bragazzi, BS, RN

Latest:

Second Primary Malignancies More Deadly in Younger Cancer Patients

Younger cancer survivors experience worse survival outcomes following a second primary cancer diagnosis than their older counterparts, according to a recent study.


Michelle Cavanaugh, RN, CPC

Latest:

Top Ten ICD-10 Tips for Oncology Practices

In the long term, ICD-10 has the potential to benefit oncology through improved data collection, but right now, practices just need to focus on preparing for the change. Here are 10 tips for oncologists.


Michelle D. Bishop, PhD

Latest:

Commentary (Bishop/Wingard)-Patient-Physician Communication in Oncology: What Does the Evidence Show?

As noted by Back,[1] the primarygoals of effective patient-physician communicationare to enhance patient understandingof the illness, to improvedecision-making, and to facilitate patientadjustment. These three goalsare sensible and important concernsof the communication dyad. A numberof studies have examined variousaspects of the communication processand the factors that influence communicationoutcomes, and a few evenhave tested interventions to improvephysician communication skills. However,there remains a dearth of studiesthat examine communication effectson the three major goals articulatedabove and that evaluate the effectivenessof communication skill interventionsin influencing patient outcomes.


Michelle Fanale, MD

Latest:

Commentary (Fanale/Hortobagyi): Bisphosphonates in the Prevention and Treatment of Bone Metastases

Drs. Ramaswamy and Shapiropresent a timely and comprehensivereview of the potentialuses of bisphosphonates and theirindications in the prevention and treatmentof bone metastasis. The reviewprovides a concise summary of thepathophysiology of skeletal metastasesand describes emerging biologicprinciples that open the door for novel,highly targeted therapeutic interventions.It is generally accepted thatrelative osteoclast hyperactivity resultsin excess bone resorption, which isthe basic process behind bone metastasis,osteoporosis, and hypercalcemiaof malignancy. Osteoprotegerin,the receptor activator of nuclear factor–kappa B (RANK), and the kappa Bligand (RANK-L) have critical rolesin osteoclastogenesis. In addition,parathyroid hormone–related proteinalso plays a major role in osteoblastactivation and production of RANKLas well as terminal osteoclast differentiationand activation.


Michelle Gabriel, RN, MS

Latest:

Providing Palliative Care for the Newly Diagnosed Cancer Patient: Concepts and Resources

The three words “You’ve got cancer” can change someone’s life. After being diagnosed with cancer, questions arise: Can it be cured? Why me? Am I going to die? Luckily, as advances have been made in the treatment of cancer, the diagnosis of cancer is not necessarily a terminal one. In fact, many cancers, such as breast or colon cancer, when detected early enough, are curable, and treatment advances have resulted in long-term survivorship across many cancers.


Michelle Geller, MD

Latest:

Commentary (Chlebowski/Geller)-Obesity and Cancer: The Risks, Science, and Potential Management Strategies

Anne McTiernan has provideda comprehensive and balancedreview of a complex topic,namely, “Obesity and Cancer: TheRisks, Science, and Potential ManagementStrategies.” The impressiveweight of assembled evidence from thecited observational studies has been sufficientto influence several cancer organizations,including the AmericanCancer Society and the American Institutefor Cancer Prevention, to issuerecommendations regarding nutritionand physical activity in relationship tocancer.[1,2] However, clinical practiceis unlikely to undergo substantialchange in the absence of prospectivetrials demonstrating benefit on clinicaloutcomes.[3] For at least the breast cancerand obesity question, informationfrom phase III randomized, prospectiveclinical trials evaluating lifestyleintervention influence on clinical outcomeare anticipated in the near future.


Michelle Goodman, RN, MS

Latest:

Cancer Nursing: Principles and Practice, 5th Edition

Cancer Nursing: Principles and Practice is widely considered to be the basic textbook on cancer nursing. With this edition, every chapter has been updated to reflect the latest research and references, and many of the chapters now include


Michelle Purdom, RN

Latest:

Clinical Management of EGFRI Dermatologic Toxicities: The Nursing Perspective

All nursing personnel actively participate in the nursing process, with the registered nurse taking primary responsibility. Five steps in the nursing process include assessment, diagnosis, planning, implementation, and evaluation. Health-care professionals have more than 10 years of experience with EGFR inhibitors in the oncology setting. To date, the application of the nursing process to assist in patient management has not been previously published or thoroughly described in the literature. This article will apply the nursing process utilizing current recommendations regarding the assessment and management of dermatologic toxicities associated with EGFR inhibitors.


Michelle Zeidler, MD

Latest:

Radiofrequency Ablation in Lung Cancer: Promising Results in Safety and Efficacy

Only about 15% of patients diagnosed with lung carcinoma eachyear are surgical candidates, either due to advanced disease orcomorbidities. The past decade has seen the emergence of minimallyinvasive therapies using thermal energy sources: radiofrequency,cryoablation, focused ultrasound, laser, and microwave; radiofrequencyablation (RFA) is the best developed of these. Radiofrequency ablationis safe and technically highly successful in terms of initial ablation.Long-term local control or complete necrosis rates drop considerablywhen tumors are larger than 3 cm, although repeat ablations can beperformed. Patients with lung metastases tend to fare better with RFlung ablation than those with primary lung carcinoma in terms of localcontrol, but it is unclear if this is related to smaller tumor size at time oftreatment, lesion size uniformity, and sphericity with lung metastases,or to differences in patterns of pathologic spread of disease. The effectsof RFA on quality of life, particularly dyspnea and pain, as well aslong-term outcome studies are generally lacking. Even so, the resultsregarding RF lung ablation are comparable to other therapies currentlyavailable, particularly for the conventionally unresectable or high-risklung cancer population. With refinements in technology, patient selection,clinical applications, and methods of follow-up, RFA will continueto flourish as a potentially viable stand-alone or complementarytherapy for both primary and secondary lung malignancies in standardand high-risk populations.


Michio Mito, MD, PhD

Latest:

UFT and Mitomycin Plus Tamoxifen for Stage II, ER-Positive Breast Cancer

A trial was designed to examine the combination of UFT and mitomycin (Mutamycin) plus tamoxifen (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive


Miguel A. Sanz, MD, PhD

Latest:

Arsenic Trioxide in the Management of APL: Proceed With Caution

In this excellent review of acute promyelocytic leukemia (APL) treatment, the authors highlight opportunities offered by incorporating arsenic trioxide (ATO) into the therapeutic armamentarium.


Miguel A. Villalona-calero, MD

Latest:

Mitomycin as a Modulator of Irinotecan Anticancer Activity

Irinotecan and mitomycin (Mutamycin) possess significant single-agent activity against several tumor types, and mitomycin activates topoisomerase I, the cellular target of irinotecan. We conducted a phase I dose-escalation study of irinotecan and mitomycin in 37 evaluable patients with solid tumors. Antitumor responses included 2 complete responses, 5 partial responses, 10 minor responses, and a CA 19-9 tumor marker response.


Miguel Alvelo-rivera, MD

Latest:

Neoadjuvant Chemotherapy for Resectable Non–Small-Cell Lung Cancer

Lung cancer is the most common cancer diagnosed in men and women in the United States, and is the leading cause of cancer death.Over 160,000 individuals died as a result of lung cancer in 2008.[1] This number amounted to more than the number of deaths from colon, breast, and prostate cancers combined. The majority of lung cancer cases are non–small-cell lung cancer (NSCLC), and the poor outcomes are attributed to the high rate of metastases associated with this disease.



Miguel Rodriguez-Bigas, MD

Latest:

Colon, Rectal, and Anal Cancers

This management guide covers the risk factors, symptoms, diagnosis, staging, and treatment of colorectal and anal cancers.


Mihir K. Bhayani, MD

Latest:

A Shifting Paradigm for Patients with Head and Neck Cancer: Transoral Robotic Surgery (TORS)

The evolution of surgical oncologic technology has moved toward reducing patient morbidity without compromising oncologic resection. In head and neck surgery, organ-preserving techniques have paved the way for the development of transoral techniques that remove tumors of the upper aerodigestive tract without external incisions and potentially spare the patient adjuvant treatment. The introduction of transoral robotic surgery (TORS) improves upon current transoral techniques to the oropharynx and supraglottis. This review will report on the evolution of robotic-assisted surgery: We will cover its applications in head and neck surgery by examining early oncologic and functional outcomes, training of surgeons, costs, and future directions.


Mikael L. Rinne, MD, PhD

Latest:

Treating Anaplastic Oligodendrogliomas and WHO Grade 2 Gliomas: PCV or Temozolomide? The Case for Temozolomide

There is no evidence that PCV is more effective than TMZ for the treatment of glioblastoma. However, there is unequivocal evidence that PCV is more toxic than TMZ.


Mikaela Olsen, RN, MS

Latest:

Management of Delirium

Ms. B is a 44-year-old married African-American female who was diagnosed with locally advanced right breast cancer in 2002. Immunohistochemistry in the original tumor was estrogen- and progesterone-receptor-negative, HER2-positive. Her past medical history is significant for hypertension and miscarriage in 1995.


Mike Chen, MD, PhD

Latest:

Current and Emerging Treatments for Brain Metastases

Conventional methods for treating brain metastasis, such as surgery, WBRT, and SRS, each compete with and complement one another. A plethora of recent studies have helped define and expand the utility of these tools.